Research |
![]() ![]() ![]() ![]() ![]() |
Serial Number | 87886335 |
Registration Number | 6004952 |
Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
Domestic Representative | Frances M. Jagla |
Attorney Name | Frances M. Jagla |
Attorney Docket Number | 130785.0047 |
Law Office Assigned | M10 |
Employee Name | KHOURI, SANI PHILIPPE |
2018-04-20 | Application Filed |
2019-05-05 | Location: TMO LAW OFFICE 110 - EXAMINING ATTORNEY ASSIGNED |
2019-05-05 | Status: Live/Pending |
2019-10-25 | Transaction Date |
2019-12-24 | Published for Opposition |
2020-03-10 | Trademark Registered |
Owner: | ![]() |
Address | Ash Road, Wrexham Industrial Estate Wrexham GB LL139UF |
Legal Entity Type | Corporation |
Legal Entity State | GB |
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
International Codes: | 42 |
U.S. Codes: | 100,101 |
Type Code | Type |
---|---|
GS0051 | Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, and for cardiovascular and cognitive disorders; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment and prevention of neuromuscular disorders, muscle disorders orthopedic disorders, disorders relating to age; pharmaceutical preparations for the treatment of pain, muscle spasm, hemifacial spasm and blepharospasm; pharmaceutical preparations for the treatment and prevention of cervical dystonia, torticollis, cerebral palsy, and spasticity; pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other derivatives for use in the treatment of excessive sweating, neuromuscular disorders, muscle disorders, orthopedic disorders, disorders relating to age, pain, muscle spasm, hemifacial spasm and blepharospasm, cervical dystonia, torticollis, cerebral palsy, and spasticity, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin |
GS0051 | Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, and for cardiovascular and cognitive disorders; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment and prevention of neuromuscular disorders, muscle disorders orthopedic disorders, disorders relating to age; pharmaceutical preparations for the treatment of pain, muscle spasm, hemifacial spasm and blepharospasm; pharmaceutical preparations for the treatment and prevention of cervical dystonia, torticollis, cerebral palsy, and spasticity; pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other derivatives for use in the treatment of excessive sweating, neuromuscular disorders, muscle disorders, orthopedic disorders, disorders relating to age, pain, muscle spasm, hemifacial spasm and blepharospasm, cervical dystonia, torticollis, cerebral palsy, and spasticity, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin |
Description | Date | Event Coding |
---|---|---|
NEW APPLICATION ENTERED IN TRAM | 2018-04-24 | 1 NWAP I:Incoming Correspondence |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-05-01 | 2 NWOS I:Incoming Correspondence |
ASSIGNED TO EXAMINER | 2018-08-10 | 3 DOCK D:Assigned to Examiner |
NON-FINAL ACTION WRITTEN | 2018-08-13 | 4 CNRT R:Renewal |
NON-FINAL ACTION E-MAILED | 2018-08-13 | 5 GNRT F:First Action |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2018-08-13 | 6 GNRN O:Outgoing Correspondence |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-02-12 | 7 TROA I:Incoming Correspondence |
ASSIGNED TO LIE | 2019-02-19 | 8 ALIE A:Allowance for Publication |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-02-22 | 9 CRFA I:Incoming Correspondence |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-02-22 | 10 TEME I:Incoming Correspondence |
NON-FINAL ACTION WRITTEN | 2019-03-15 | 11 CNRT R:Renewal |
NON-FINAL ACTION E-MAILED | 2019-03-15 | 12 GNRT O:Outgoing Correspondence |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2019-03-15 | 13 GNRN O:Outgoing Correspondence |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-04-15 | 14 TROA I:Incoming Correspondence |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-04-22 | 15 CRFA I:Incoming Correspondence |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-04-22 | 16 TEME I:Incoming Correspondence |
NON-FINAL ACTION WRITTEN | 2019-05-05 | 17 CNRT R:Renewal |
NON-FINAL ACTION E-MAILED | 2019-05-05 | 18 GNRT O:Outgoing Correspondence |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2019-05-05 | 19 GNRN O:Outgoing Correspondence |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-10-25 | 20 TROA I:Incoming Correspondence |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-11-04 | 21 CRFA I:Incoming Correspondence |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-11-04 | 22 TEME I:Incoming Correspondence |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2019-11-20 | 23 CNSA O:Outgoing Correspondence |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-12-04 | 24 NONP E:E-Mail |
PUBLISHED FOR OPPOSITION | 2019-12-24 | 25 PUBO A:Allowance for Publication |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-12-24 | 26 NPUB E:E-Mail |
REGISTERED-PRINCIPAL REGISTER | 2020-03-10 | 27 R.PR A:Allowance for Publication |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.